ReviewAnnals of surgical oncology2026
Pregnancy-Associated Breast Cancer: A Trimester and Subtype Based Clinical Decision Framework for the Surgeon and Surgical Trainee.
Review in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Does the Axilla Still Matter? Rethinking Nodal Staging in the Era of CDK4/6 Inhibition.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPregnancy-associated breast cancer (PABC), defined as breast cancer diagnosed during pregnancy or within 1 year postpartum, presents unique surgical and oncologic challenges. Management requires balancing maternal outcomes with fetal safety while accounting for trimester-specific constraints and tumor biology.
methodsWe conducted a comprehensive narrative review of the literature on the management of operable PABC. Evidence was synthesized into a trimester-based clinical framework incorporating surgical approach, axillary staging, systemic therapy, tumor subtype, and reconstructive considerations.
resultsSurgery is safe across all trimesters and remains the cornerstone of treatment. In the first trimester, mastectomy is generally preferred given contraindications to chemotherapy and radiotherapy during organogenesis. In the second and early third trimesters, both mastectomy and breast-conserving therapy with deferred postpartum radiation are feasible, and anthracycline- and taxane-based chemotherapy can be administered. Radiation therapy, endocrine therapy, human epidermal growth factor receptor 2 (HER2)-directed therapy, and immunotherapy are contraindicated during pregnancy. Management of aggressive subtypes, including HER2-positive and triple-negative disease, requires modification of standard neoadjuvant regimens because of fetal toxicity. Sentinel lymph node biopsy with technetium-99m sulfur colloid is safe, whereas blue dye should be avoided. Immediate expander-based reconstruction may be considered in select patients but is often deferred.
conclusionsOptimal management of PABC requires trimester- and subtype-specific decision-making within a multidisciplinary framework. This review provides a practical, clinically applicable algorithm to guide management. When timely, guideline-concordant care is delivered, maternal outcomes approach those of nonpregnant patients.
Indexed as
Identifiers
42390665What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.